{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:13:00Z","timestamp":1792699980718,"version":"4.5.0"},"reference-count":48,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Int AIDS Soc."],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Reductions in HIV acquisition have slowed, and the global community is significantly off track from global goals. Oral pre\u2010exposure prophylaxis (PrEP) alone cannot address the diverse needs of the millions of people at risk of HIV acquisition. Long\u2010acting injectable cabotegravir (CAB\u2010LA) received United States Food and Drug Administration approval for HIV prevention in December 2021. When studied, CAB\u2010LA demonstrated high effectiveness, provides months of protection versus daily use, is preferred by some users and has the potential to achieve commodity cost reduction. These factors position CAB\u2010LA to catalyse transformation in HIV prevention. Significant work must be undertaken to ensure at\u2010scale uptake in low\u2010 and middle\u2010income countries. Leveraging decades of product introduction experience, Clinton Health Access Initiative (CHAI) has developed an innovative roadmap to support equitable CAB\u2010LA introduction, comprising tightly executed market\u2010shaping, product development, regulatory, and programmatic and implementation action.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Proven models exist (e.g. long\u2010acting reversible contraceptives, paediatric tuberculosis treatment and antiretrovirals (ARVs), such as paediatric dolutegravir and tenofovir disoproxil fumarate, lamivudine, and dolutegravir) for partnership\u2010driven, accelerated, impactful product introduction. Based on learnings from these models and needs in the prevention space, CHAI developed a roadmap to maximize the near\u2010term impact of CAB\u2010LA and accelerate the development of, access to and impact of quality\u2010assured, low\u2010cost generic CAB\u2010LA. This roadmap is intended to inform introduction planning and investment decision\u2010making across a range of stakeholders, including donors, governments, manufacturers and other partners working in the HIV prevention space. Elements include (1) ensuring coordination and alignment across partners, and avoiding redundancy experienced during oral PrEP introduction; (2) preparing national programmes and providing support to maximize impact, including the development of national policies, guidelines and introduction plans; system strengthening; quantification and procurement; and addressing evidence needs, among other areas; (3) supporting community engagement, ensuring that demand generation and delivery approaches are person\u2010centred and community\u2010led; (4) incentivizing generic product development through, for example, milestone\u2010based commercialization incentives and product development cost\u2010sharing; and (5) expediting regulatory reviews.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Accelerating access to affordable, generic CAB\u2010LA can transform progress towards HIV epidemic control. This vision of impact at scale in prevention is achievable, if informed by results\u2010backed approaches to introduction.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jia2.26101","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:10:36Z","timestamp":1689232236000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Securing accelerated access to long\u2010acting injectable cabotegravir for HIV prevention in low\u2010 and middle\u2010income countries"],"prefix":"10.1002","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5667-095X","authenticated-orcid":false,"given":"Sarah Y.","family":"Jenkins","sequence":"first","affiliation":[{"name":"Clinton Health Access Initiative  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Resar","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9312-7083","authenticated-orcid":false,"given":"Zachary","family":"Panos","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Staple","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melynda","family":"Watkins","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ripin","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Amole","sequence":"additional","affiliation":[{"name":"Clinton Health Access Initiative  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,13]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"UNAIDS.AIDSInfo[Internet].2022[cited 2022 Aug 28]. Available from:https:\/\/aidsinfo.unaids.org\/"},{"key":"e_1_2_9_3_1","unstructured":"UNAIDS.Global AIDS Strategy 2021\u20132026[Internet].2021March 25 [cited 2022 Sept 1]. Available from:https:\/\/www.unaids.org\/en\/resources\/documents\/2021\/2021\u20102026\u2010global\u2010AIDS\u2010strategy"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.9745\/GHSP-D-13-00010"},{"key":"e_1_2_9_5_1","unstructured":"US FDA.Truvada for PrEP Fact Sheet: ensuring safe and proper use[Internet].2012. [cited 2022 Aug 28]. Available from:https:\/\/www.fda.gov\/media\/83586\/download"},{"key":"e_1_2_9_6_1","unstructured":"AVAC.The Global PrEP Tracker[Internet].2020[updated 2022 July; cited 2022 Aug 28] Available from:https:\/\/data.prepwatch.org\/"},{"key":"e_1_2_9_7_1","unstructured":"United Nations.Resolution adopted by the General Assembly on 8 June 2016[Internet].2016June 20 [cited 2022 Aug 28]. Available from:https:\/\/www.unaids.org\/en\/resources\/documents\/2016\/2016\u2010political\u2010declaration\u2010HIV\u2010AIDS"},{"key":"e_1_2_9_8_1","unstructured":"United Nations.Political Declaration on HIV and AIDS: Ending Inequalities and Getting on Track to End AIDS by 2030[Internet].2021June 8 [cited 2022 Aug 28]. Available from:https:\/\/www.unaids.org\/en\/resources\/documents\/2021\/2021_political\u2010declaration\u2010on\u2010hiv\u2010and\u2010aids"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-03145-0"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258542"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0228620"},{"key":"e_1_2_9_12_1","unstructured":"FDA approves first injectable treatment for HIV pre\u2010exposure prevention [Internet]. U.S. Food and Drug Administration. FDA; [cited 2022 Jun 20]. Available from:https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010injectable\u2010treatment\u2010hiv\u2010pre\u2010exposure\u2010prevention"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101016"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00538-4"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2018.1511346"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25408"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-022-03575-y"},{"issue":"4","key":"e_1_2_9_18_1","first-page":"394","article-title":"Young women's stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa","volume":"80","author":"Minnis AM","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"e_1_2_9_19_1","unstructured":"CHAI.Understanding manufacturing and cost for HIV prevention game changer: generic CAB\u2010LA COGS analysis and FAQ brief[Internet].2022October 12 [cited 2022 Oct 17] Available from:https:\/\/www.clintonhealthaccess.org\/blog\/understanding\u2010manufacturing\u2010and\u2010cost\u2010for\u2010hiv\u2010prevention\u2010game\u2010changer\u2010generic\u2010cab\u2010la\u2010cogs\u2010analysis\u2010and\u2010faq\u2010brief\/"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1071\/SH18125"},{"key":"e_1_2_9_21_1","unstructured":"World Health Organization.Guidelines on long\u2010acting injectable cabotegravir for HIV prevention.Geneva:World Health Organization;2022."},{"key":"e_1_2_9_22_1","unstructured":"AVAC.Translating scientific advance into public health impact: a plan for accelerating access and introduction of injectable CAB for PrEP[Internet].2022June [cited 2023 Mar 29] Available from:https:\/\/www.avac.org\/resource\/translating\u2010scientific\u2010advance\u2010public\u2010health\u2010impact\u2010plan\u2010accelerating\u2010access\u2010and"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac753"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002951"},{"key":"e_1_2_9_25_1","unstructured":"UNAIDS CHAI Bill and Melinda Gates Foundation UKAID Global Fund USAID Unitaid.New high\u2010quality antiretroviral therapy to be launched in South Africa Kenya and over 90 low\u2010 and middle\u2010income countries at reduced price[Internet].2021September 21 [cited 2022 Sept 1] Available from:https:\/\/www.unaids.org\/sites\/default\/files\/20170921_PR_TLD_en.pdf"},{"key":"e_1_2_9_26_1","unstructured":"CHAI.HIV Market Report 2019[Internet]. September 2019 [cited 2022 Sept 1] Available from:http:\/\/clintonhealthaccess.org\/wp\u2010content\/uploads\/2019\/12\/2019\u2010HIV\u2010Market\u2010Report.pdf"},{"key":"e_1_2_9_27_1","unstructured":"CHAI.HIV Mid\u2010Year Market Memo 2022[Internet].2022May 31 [cited 2022 Sept 1] Available from:https:\/\/www.clintonhealthaccess.org\/report\/hiv\u2010mid\u2010year\u2010market\u2010memo\u20102022"},{"key":"e_1_2_9_28_1","unstructured":"Bill and Melinda Gates Foundation.Innovative partnership reduces cost of Bayer's long\u2010acting reversible contraceptive implant by more than 50 percent. [Internet]2013February 27 [cited 2022 Sept 1]. Available from:https:\/\/www.gatesfoundation.org\/ideas\/media\u2010center\/press\u2010releases\/2013\/02\/partnership\u2010reduces\u2010cost\u2010of\u2010bayers\u2010reversible\u2010contraceptive\u2010implant"},{"key":"e_1_2_9_29_1","unstructured":"Unitaid\/WHO\/UNAIDS\/Global Fund\/AVAC.Coalition to accelerate access to long\u2010acting PrEP[Internet].2022July [cited 2022 Aug 29] Available from:https:\/\/www.avac.org\/sites\/default\/files\/u3\/Access\u2010Coalition\u2010Backgrounder.pdf?utm_source=AVAC%20Email%20Updates&utm_campaign=157011ac52\u2010EMAIL_CAMPAIGN_2022_06_07_02_20_COPY_02&utm_medium=email&utm_term=0_6fd730be57\u2010157011ac52\u2010"},{"key":"e_1_2_9_30_1","unstructured":"TB Alliance\/Unitaid.New pathways for childhood TB treatment. [Internet]2017[cited 2023 Mar 29]. Available from:https:\/\/www.tballiance.org\/sites\/default\/files\/child\u2010resources\/New_Pathways_for_Childhood_TB_Treatment.pdf"},{"key":"e_1_2_9_31_1","unstructured":"Prevention Market Manager.Analysis of BMGF\u2010Funded PrEP Demonstration Projects. [Internet]2019January 18 [cited 2023 Mar 29] Available from:https:\/\/www.prepwatch.org\/resources\/bmgf\u2010funded\u2010demo\u2010projects\/"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462420943704"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25208"},{"key":"e_1_2_9_34_1","unstructured":"CHAI.2021 HIV market report: the state of the HIV market in low\u2010 and middle\u2010income countries. [Internet]2021October 12 [cited 2023 Mar 29] Available from:https:\/\/www.clintonhealthaccess.org\/report\/2021\u2010hiv\u2010market\u2010report\u2010the\u2010state\u2010of\u2010the\u2010hiv\u2010market\u2010in\u2010low\u2010and\u2010middle\u2010income\u2010countries\/"},{"key":"e_1_2_9_35_1","unstructured":"FHI360.MOSAIC Project Overview. [Internet]2022July [cited 2022 Sept 1] Available from:https:\/\/www.fhi360.org\/resource\/mosaic\u2010project\u2010overview"},{"key":"e_1_2_9_36_1","unstructured":"Unitaid.Unitaid to introduce new long\u2010lasting injection to prevent HIV in Brazil and South Africa as high\u2010income countries begin deployment. [Internet]2022March 18 [cited 2022 Sept 1]. Available from:https:\/\/unitaid.org\/news\u2010blog\/unitaid\u2010to\u2010introduce\u2010new\u2010long\u2010lasting\u2010injection\u2010to\u2010prevent\u2010hiv\u2010in\u2010brazil\u2010and\u2010south\u2010africa\u2010as\u2010high\u2010income\u2010countries\u2010begin\u2010deployment\/#en"},{"key":"e_1_2_9_37_1","unstructured":"UNAIDS.Global AIDS Update 2022: In Danger. [Internet]2022July 27 [cited 2022 Sept 1]. Available from:https:\/\/www.unaids.org\/en\/resources\/documents\/2022\/in\u2010danger\u2010global\u2010aids\u2010update"},{"key":"e_1_2_9_38_1","unstructured":"CAB\u2010LA Community Forum.Community Position Statement[Internet]2022July [cited 2022 Sept 1]. Available from:http:\/\/www.afrocab.info\/wp\u2010content\/uploads\/2022\/03\/CAB\u2010LA\u2010Community\u2010Statement\u2010Final.pdf"},{"key":"e_1_2_9_39_1","unstructured":"CAB\u2010LA Community Forum.Community response to ViiV's recent statement on CAB\u2010LA.2022March [cited 2022 Sept 1]. Available from:http:\/\/www.afrocab.info\/wp\u2010content\/uploads\/2022\/03\/CAB\u2010LA\u2010Community\u2010Response\u2010Letter.pdf"},{"key":"e_1_2_9_40_1","unstructured":"CAB\u2010LA Community Forum.CAB\u2010LA Community Forum Statement. [Internet]2022July [cited 2022 Sept 1]. Available from:http:\/\/www.afrocab.info\/wp\u2010content\/uploads\/2022\/07\/CAB\u2010LA\u2010FORUM\u2010STATEMENT.pdf"},{"key":"e_1_2_9_41_1","unstructured":"African Women Living with HIV.Communique of the Kigali dolutegravir stakeholder meeting of African women living with HIV. [Internet]2019May [cited 2022 Sept 1] Available from:http:\/\/www.afrocab.info\/wp\u2010content\/uploads\/2019\/05\/Kigali\u2010Communique\u2010.pdf"},{"key":"e_1_2_9_42_1","unstructured":"CHAI.Pediatric DTG community resources. [Internet]2021July [cited 2022 Sept 1] Available from:https:\/\/www.newhivdrugs.org\/pdtg\u2010community\u2010resources"},{"key":"e_1_2_9_43_1","unstructured":"PEPFAR.PEPFAR ARV formulation priorities. [Internet]2018November [cited 2023 Mar 29] Available from:https:\/\/www.state.gov\/pepfar\u2010arv\u2010formulation\u2010priorities\u20102\/"},{"key":"e_1_2_9_44_1","unstructured":"SantosR FletcherER.Despite reforms WHO \u2018Prequalification\u2019 Program for vital medicines and diagnostics is inconsistent and full of delays. Health Policy Watch[Internet]2022November 8 [cited 2022 Sept 1] Available from:https:\/\/healthpolicy\u2010watch.news\/who\u2010prequalification\u2010program\/"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-017-0210-x"},{"key":"e_1_2_9_46_1","unstructured":"World Health Organization.FPPs & APIs eligible for prequalification (\u201cEOIs\u201d). [Internet] [cited 2022 Sept 1]. Available from:https:\/\/extranet.who.int\/pqweb\/medicines\/products\u2010eligible\u2010prequalification"},{"key":"e_1_2_9_47_1","unstructured":"US Food & Drug Administration.Upcoming product\u2010specific guidances for complex generic drug product development. [Internet]2022August [cited 2022 Sept 1] Available from:https:\/\/www.fda.gov\/drugs\/guidances\u2010drugs\/upcoming\u2010product\u2010specific\u2010guidances\u2010complex\u2010generic\u2010drug\u2010product\u2010development"},{"key":"e_1_2_9_48_1","unstructured":"UNAIDS World Health Organization.Uneven progress on voluntary medical male circumcision[Internet].2022April [cited 2022 Sept 1] Available from:https:\/\/www.malecircumcision.org\/resource\/uneven\u2010progress\u2010vmmc\u2010unaids\u2010and\u2010who\u2010progress\u2010brief\u2010april\u20102022\u20102007%E2%80%932020"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1177\/0956462418787896"}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.26101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T02:05:26Z","timestamp":1743905126000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.26101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":48,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1002\/jia2.26101"],"URL":"https:\/\/doi.org\/10.1002\/jia2.26101","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2022-10-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e26101"}}